Listen to the audio version of this article (generated by AI).
Listen to the audio version of this article (generated by AI).
Revenue climbed 8% to HUF 929 bln.
Cost of sales rose at nearly the same pace to HUF 288.1 bln. Operating profit increased 12% to HUF 292.9 bln as spending on R&D declined. Richter noted that the drop was mainly in the biotechnology business segment. R&D spending stood at 10% of sales in 2025, it added.
Richter booked a net financial loss of HUF 10.8 bln after a HUF 12.9 bln net gain in the base period as the dollar weakened and the forint firmed. Most of the foreign exchange losses were unrealized, Richter said.
Earnings per share came to HUF 1,271 for the year.
North America was Richter’s biggest market in 2025, generating pharmaceutical revenue of HUF 276.4 bln. Royalties from sales of Vraylar, the brand name there for Richter’s antipsychotic cariprazine, rose 9% to HUF 250 bln.
Sales in Eastern Europe came to HUF 185.8 bln and sales in Central Europe reached HUF 176.4 bln. In Western Europe, sales revenue was HUF 179.0 bln.
At a press conference after the release of the report, Richter CEO Gábor Orbán said pharmaceuticals revenue could climb “in the high single digits,” at constant exchange rates, in 2026.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
